Voloridge Investment Management
KLRS

Voloridge Investment Management’s Kalaris Therapeutics KLRS Stock Holding History

Voloridge Investment Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,239
Closed -$563K – 1910
2021
Q2 		$563K Buy
+1,239
New +$640K ﹤0.01% 1410

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Voloridge Investment Management's KLRS Position: Q3 2021 in Review

Voloridge Investment Management sold out of Kalaris Therapeutics (KLRS) in Q3 2021, closing a stake of 1,239 shares — an estimated $563K sold.

Voloridge Investment Management first reported a position in KLRS in Q2 2021 and held it in 1 quarter. The position peaked at $563K in Q2 2021. 79 funds tracked by Wall St. Rank hold KLRS as of Q3 2021.

  • Voloridge Investment Management reported no remaining Kalaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Voloridge Investment Management sold 1,239 Kalaris Therapeutics shares in Q3 2021, an estimated $563K.
  • Voloridge Investment Management first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 1 quarter.
  • Voloridge Investment Management's Kalaris Therapeutics position peaked at $563K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2021.

Based on Voloridge Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.